Introduction {#s1}
============

Skeletal muscle cells (myofibers) are large, syncytial cells which can span the entire length of a limb segment: in humans, the sartorius muscle can be \~60 cm long, with individual muscle fibers longer than 20 cm ([@bib11]). Myofibers are generated by the fusion of terminally postmitotic myocytes, which differentiate from proliferation-competent myoblasts. Due to the linear, one-way succession of proliferating myoblast to differentiated myocyte to syncytial myofiber, transitions between states are tightly regulated: either failure to progress from myoblast to myocyte or precocious differentiation from myoblast to myocyte will lead to a deficit of functional contractile muscle. Because of the syncytial nature of myofibers, in skeletal muscle there exists an additional aspect of the decision to commit to differentiation: terminally-differentiated myocytes must have a sufficient number of other fusion-competent myocytes in close proximity to fuse with, or they cannot generate a functional myofiber.

It is a common observation that sparse plating of myogenic cells in vitro delays myogenic differentiation, while cells cultured at higher confluence exhibit a much higher degree of differentiation regardless of pro-mitogenic conditions such as high serum. This has been described as a version of the 'community effect', a phenomenon first noted by John Gurdon in the context of amphibian muscle development ([@bib9]). He found that single mesoderm cells or aggregates of less than 100 mesoderm cells will not express MyoD and differentiate into muscle even under conditions that promote myogenesis, while aggregates of 100 or more cells would differentiate efficiently ([@bib10]); later experiments showed that the homotypic cell-cell adhesion molecule N-cadherin is responsible for at least a portion of this effect ([@bib16]). Similar studies in mouse suggested that a minimum of 30--40 cells is required for myogenic differentiation ([@bib7]). As noted earlier, skeletal muscle fibers are syncytial cells formed following permanent withdrawal of myogenic precursors from the cell cycle: it would make sense that before committing to such a course of action, a potential myocyte would like some assurances that if it 'takes the plunge', other differentiated cells would be available for fusion. Similarly, it seems practical for a signal conveying this information to be contact-mediated.

Ephs are a family of receptor tyrosine kinases that act via juxtacrine interactions with cells presenting their ligands (ephrins) to modify cell motility, assortment, proliferation, differentiation, and survival in multiple tissue types ([@bib20]; [@bib21]; [@bib18]). Here we present data suggesting that EphA7, a member of this family of bidirectional signaling molecules, is a potent mediator of the community effect. EphA7 is expressed during muscle development and regeneration on differentiated myocytes and nascent myofibers; myogenic cells lacking EphA7 exhibit delayed and prolonged differentiation in vitro and in vivo; and exposing myogenic cells (with or without endogenous EphA7) to EphA7 ectodomain accelerates differentiation. We propose a model in which EphA7 expression on differentiated myocytes promotes synergistic differentiation of adjacent myoblasts. Early-expressing cells differentiate stochastically and express EphA7, which then promotes differentiation and EphA7 expression in adjacent cells, which then promote differentiation and EphA7 expression in cells adjacent to them, etc. We propose that juxtacrine signaling via EphA7 provides a mechanism to promote collective differentiation in myogenic populations, to ensure that myoblasts are in close proximity to fusion-competent myocytes before they commit to terminal differentiation.

Results {#s2}
=======

EphA7 is expressed by differentiated myocytes and nascent myofibers in vivo and in vitro {#s2-1}
----------------------------------------------------------------------------------------

Our initial observations in an expression screen for Eph/ephrins in the context of adult skeletal muscle regeneration suggested that EphA7, while absent during muscle homeostasis, is transiently upregulated by regenerating myofibers in vivo after a barium chloride (BaCl~2~) injury ([@bib40]). This expression pattern raised the possibility that EphA7 might function during satellite cell differentiation and/or fusion during the acute stages of muscle differentiation. To define when and where EphA7 is expressed during regeneration, we stained sections of uninjured adult mouse tibialis anterior (TA) muscles in parallel with sections of TAs at 3, 5, 7, 10, 16, and 21 days post injury (dpi) following BaCl~2~ injury for EphA7, and costained with laminin to identify myofiber boundaries and embryonic myosin heavy chain (eMyHC) to identify newly-generated myofibers ([Figure 1A](#fig1){ref-type="fig"}). We noted that EphA7 protein was consistently expressed by nascent myofibers at all timepoints examined, and that as muscle regeneration was resolved, muscle fiber caliber increased, and eMyHC expression was lost, EphA7 expression was also extinguished ([Figure 1B](#fig1){ref-type="fig"}). Because multiple splice isoforms of EphA7 exist and the antibody used cannot distinguish between them, we performed RT-PCR on injured and uninjured TA muscle to identify potential alternative splice isoforms and to correlate protein expression with mRNA expression. We found that full-length EphA7 is the most abundant isoform expressed during muscle regeneration, although both truncated isoforms were also detected at varying levels. ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}).

![EphA7 expression is restricted to nascent myofibers after injury.\
(**A**) Timecourse of sections of the TA muscle after partial injury via BaCl~2~ injection. Indirect immunohistochemistry with anti-EphA7 (green), anti-laminin (white) and anti-eMyHC (red) shows that eMyHC expression and EphA7 expression both begin shortly after injury (3 days) and are extinguished when the injury is resolved (by 21 days.) EphA7 staining is limited to laminin^+^ profiles (nascent or hypertrophying myofibers). T = days post-injury (dpi), boxes indicate regions of color-separated insets. Scale bars = 200 μm in main images, 60 μm in enlarged insets. (**B**) Coexpression of EphA7 and eMyHC over the timecourse of injury. At early timepoints EphA7 and eMyHC are uniformly coexpressed; as the injury resolves (starting at seven dpi) EphA7 and the eMyHC are downregulated. Infrequent fibers (0.3--1.5%) at later timepoints were scored positive for EphA7 but negative for eMyHC based on staining intensity thresholds.\
Figure 1---source data 1.EphA7 and embryonic myosin heavy chain coexpression during regeneration.](elife-53689-fig1){#fig1}

To quantify EphA7 expression in satellite cells and their progeny, we explanted satellite cells either with or without the host myofiber and stained them with anti-EphA7 alone and in conjunction with anti-Pax7 (to mark myogenic progenitors), anti-MyoD (to mark myoblasts/myocytes), or anti-myogenin (to mark differentiated myocytes). When satellite cells were isolated and cultured in association with their host myofiber, expression of EphA7 was first detected on relatively few cells at 48 hours after isolation, but was seen on the majority of satellite cells by 96 hours in culture ([Figure 2A](#fig2){ref-type="fig"}). In monoculture, EphA7 expression is detectable only in a few dispersed cells when they are initially plated under low serum conditions ([Figure 2B](#fig2){ref-type="fig"}), but one day later it is present in individual cells or more often groups of cells in close association with one another and/or with bipolar morphology suggesting differentiation. After three days in low serum, the majority of cells are EphA7^+^. At all timepoints tested we saw that expression of EphA7 and Pax7 are mutually exclusive, while EphA7 and myogenin are uniformly coexpressed, suggesting that EphA7 expression is restricted to committed myocytes ([Figure 2C](#fig2){ref-type="fig"}). MyoD, which is expressed by both proliferating and differentiating myogenic cells, is present in a subset of EphA7^+^ cells, presumably differentiated myocytes.

![EphA7 is upregulated on satellite cells as they commit to differentiation.\
(**A**) EphA7 expression is absent on satellite cells of freshly-isolated myofibers (marked by expression of CD34 or syndecan-4), but is detectable by 48 hours and prominent by 96 hours. Scale bars = 10 μm. (**B**) Similarly, primary satellite cells in monoculture do not express EphA7 in significant numbers when initially plated in low serum conditions (0 days); rare EphA7^+^ cells indicated by arrows. However, within 24 hours (1 day) its expression is upregulated under differentiation-promoting conditions; note that during early differentiation EphA7^+^ cells are present in clusters rather than evenly dispersed. After 3 days in differentiation medium, the majority of cells are expressing EphA7. Scale bars = 100 μm. (**C**) Expression of EphA7 is mutually exclusive with the progenitor cell marker Pax7 but always coincident with the differentiation marker myogenin, confirming specific expression in myocytes (image is of cells after 3 days in low serum). A subset of MyoD^+^ cells, which would include both myoblasts and myocytes, coexpress EphA7. Scale bars = 100 μm. Error bars = SEM, p ≤ 0.05 (\*), 0.01 (\*\*), 0.001 (\*\*\*) or 0.0001 (\*\*\*\*).\
Figure 2---source data 1.EphA7 expression and coexpression in vitro.](elife-53689-fig2){#fig2}

To ask whether EphA7 expression is also correlated with myogenic differentiation during development, we repeated the expression studies on sections of developing mouse embryos. Prior work suggests that EphA7 mRNA is present by e11.5 ([@bib1]), when myogenic differentiation in the somites and limb buds will have already begun. At e11.5, we observed EphA7 protein staining in the dermomyotome on the surface of cells also expressing MyoD ([Figure 3A](#fig3){ref-type="fig"}), although populations of MyoD^+^ cells at the dorsomedial lip (which will migrate under the dermomyotome then differentiate to form the primary myotome) and the ventrolateral lip (which will migrate to the limb buds then differentiate to form the limb musculature) do not express EphA7. When costained for myogenin in equivalent sections, EphA7^+^ cells in the somite all express myogenin, indicating that they have committed to differentiation ([Figure 3B](#fig3){ref-type="fig"}). This can be more easily noted in oblique sections through the developing somites, in which mononuclear, differentiated primary myotome fibers can be viewed from end to end; in these sections we see that the most recently-differentiated cells express myogenin but not yet EphA7 (arrow). Finally, EphA7 is expressed in all myosin heavy chain (MyHC)-expressing differentiated myocytes in the somite ([Figure 3C](#fig3){ref-type="fig"}). By e15.5, we observe EphA7 expression on differentiated, myogenin^+^/MyHC^+^ myocytes and myofibers in muscles of forelimbs ([Figure 3D](#fig3){ref-type="fig"}) and trunk (diaphragm and body wall) ([Figure 3E](#fig3){ref-type="fig"}) as well.

![EphA7 is expressed on differentiated myogenic cells during development.\
e11.5 embryos sectioned at the level of the forelimb show expression of EphA7 in differentiated myogenic cells in the somites. (**A**) While some MyoD-expressing cells in the somite coexpress EphA7, undifferentiated MyoD^+^ migratory myoblasts at the dorsal-medial lip (right panel, arrowhead) and the ventral-lateral lip (right panel, arrow) do not. (**B**) Myogenin^+^ myocytes and primary myofibers in the myotome of the somite are almost all positive for EphA7; in oblique sections (far right panel; scale bar = 50 μm) the most recently-differentiated myogenin^+^ cells (arrow) do not yet express EphA7. (**C**) Expression of myosin heavy chain in the somite is uniformly coincident with EphA7 expression. (**D, E**) In e15.5 embryos, EphA7 also identifies myofibers in the forelimb bud (anterior at top) and diaphragm/body wall muscle. Scale bars = 100 μm unless otherwise noted.](elife-53689-fig3){#fig3}

Muscles from *EphA7*^-/-^ mice are characterized by decreased myofiber size, myofiber number, myonuclear number, and progenitor cell number {#s2-2}
-------------------------------------------------------------------------------------------------------------------------------------------

To test for a functional role of EphA7 during muscle development and homeostasis, we obtained mice carrying a germline deletion of EphA7. This strain has multiple nonlethal defects in the central nervous system ([@bib36]; [@bib4]; [@bib19]) but no skeletal muscle phenotype has been described. We noted that *EphA7*^-/-^ mice are smaller than WT littermates at birth, and hindlimb muscle wet weight is reduced in adult mice ([Figure 4A](#fig4){ref-type="fig"}). The decrease appears to be due to both a reduction in myofiber number and in myofiber size ([Figure 4B](#fig4){ref-type="fig"}). In addition, myofibers from *EphA7*^-/-^ mice had fewer myonuclei and fewer myogenic precursor cells ([Figure 4C](#fig4){ref-type="fig"}) compared to WT.

![*EphA7*^-/-^ mice have reduced muscle mass caused by diminished myofiber size and number.\
(**A**) *EphA7*^-/-^ mice weigh less that WT littermates at birth and continue to have reduced muscle mass as adult animals. (**B**) This is correlated with a reduction in myofiber number as well as myofiber size. (**C**) Individual muscle fibers in *EphA7*^-/-^ mice possess fewer myonuclei and have reduced numbers of progenitor cells during homeostasis. Error bars = SEM, p ≤ 0.05 (\*), 0.01 (\*\*), or 0.001 (\*\*\*).\
Figure 4---source data 1.Morphometric analysis of EphA7-/- mice.](elife-53689-fig4){#fig4}

Muscle regeneration in *EphA7*^-/-^ mice is protracted and characterized by the persistence of immature myofibers {#s2-3}
-----------------------------------------------------------------------------------------------------------------

To test for a functional role of EphA7 during muscle regeneration, we injured TA muscles of WT and *EphA7*^-/-^ mice with the myonecrotic agent barium chloride (BaCl~2~) ([@bib2]; [@bib31]) and harvested the muscle at 5, 10, 14, and 28 dpi. As noted above, during regeneration nascent myofibers can be identified by their expression of developmental isoforms of myosin heavy chain such as eMyHC; regenerated myofibers can be identified by the presence of centrally located rather than peripheral myonuclei, a condition that persists long after regeneration has been completed ([@bib28]). While *EphA7*^-/-^ muscles do regenerate, we noted a persistence of eMyHC expression at 10 dpi, by which time eMyHC was downregulated in most regenerated fibers in WT muscles ([Figure 5A](#fig5){ref-type="fig"}). On closer examination ([Figure 5B--C](#fig5){ref-type="fig"}), some eMyHC^+^ myofiber profiles in regenerated *EphA7*^-/-^ muscle could be identified as unfused myocytes or small, mononucleated myofibers lacking a basal lamina. While muscle fiber diameter had returned to baseline by 28 days in both genotypes, hypertrophy was delayed in the *EphA7*^-/-^ muscles both initially (between 5 and 10 dpi) and later when WT fiber diameter had nearly recovered (14 dpi) ([Figure 5D](#fig5){ref-type="fig"}).

![*EphA7*^-/-^ muscles regenerate after acute injury but maturation and hypertrophy are delayed.\
(**A**) After acute injury, *EphA7*^-/-^ muscles initially possess fewer nascent (embryonic myosin heavy chain^+^) myofibers early in regeneration than WT (3 dpi). At later time points eMyHC expression persists in *EphA7*^-/-^ muscles when it has become extinguished in favor of adult isoforms in WT (7--10 dpi). (**B, C**) Closer comparison at 10 dpi shows persistent small-caliber eMyHC+ profiles in cross sections of *EphA7*^-/-^ muscles, which in sagittal section are recognizable as either small nascent myofibers with few myonuclei or differentiated but unfused myocytes (arrows). We also note eMyHC^+^ cells/processes that do not appear to possess a basal lamina (lower left), another indication of immaturity. Scale bars = 50 or 100 μm as indicated. (**D**) Quantitation of myofiber caliber in uninjured WT or *EphA7*^-/-^ muscles confirms the disparities in myofiber size between genotypes, which is eliminated in early stages of regeneration (5 dpi) but is reconstituted at 10, 14 and 28 dpi. Average myofiber area in *EphA7*^-/-^ muscles was not significantly different between 5 and 10 dpi, or in either genotype between 28 dpi and uninjured muscle. Error bars = SEM, p ≤ 0.0001 (\*\*\*\*).\
Figure 5---source data 1.Comparison of regeneration in WT and EphA7-/- muscle.](elife-53689-fig5){#fig5}

*EphA7*^-/-^satellite cells have a delayed and protracted transition from proliferating myoblasts to differentiated myocytes in vitro {#s2-4}
-------------------------------------------------------------------------------------------------------------------------------------

One possible explanation for the decreases in myonuclear number, myofiber diameter, and myofiber number observed in *EphA7*^-/-^ muscle would be a proliferation deficit in myogenic precursor cells or myoblasts. An alternative hypothesis would be that the transition from one myogenic specification state to the next is inhibited in the absence of EphA7. To determine whether there is a specific step in the sequence of myogenesis during which EphA7 is required, we assayed markers of activation, proliferation, and differentiation in WT and *EphA7*^-/-^ satellite cells in vitro. We noted that while cell proliferation and upregulation of MyoD were not significantly different between WT and *EphA7*^-/-^ satellite cells cultured on their host myofibers at 48 hours after myofibers ([Figure 6A--B](#fig6){ref-type="fig"}), upregulation of myogenin expression was greatly decreased in *EphA7*^-/-^ satellite cells at 96 hours ([Figure 6C](#fig6){ref-type="fig"}). Similarly, the fraction of satellite cells in monoculture expressing of Pax7, proliferating (not shown), and expressing MyoD ([Figure 6D](#fig6){ref-type="fig"}) did not differ between WT and *EphA7*^-/-^ cells, but expression of myogenin was significantly decreased ([Figure 6E](#fig6){ref-type="fig"}). *EphA7*^-/-^ cultures had a higher prevalence of round, birefringent cells (typical of undifferentiated myoblasts) but otherwise there were no notable differences in cell morphology in vitro.

![Upregulation of terminal differentiation markers is delayed in *EphA7*^-/-^ myoblasts.\
(**A, B**) In single fiber culture, the percentage of syndecan-4^+^ satellite cells incorporating EdU or expressing MyoD at 48 hours is not significantly different between WT and *EphA7*^-/-^. (**C**) However, *EphA7*^-/-^ satellite cells largely fail to upregulate myogenin (MyoG) at 96 hr. (**D, E**) Similarly, WT and *EphA7*^-/-^ satellite cells grown in monoculture express MyoD at statistically similar levels 48 hours after plating, but *EphA7*^-/-^ cells do not upregulate myogenin to the same extent as WT 96 hours after plating. Scale bars = 10 μm. Error bars = SEM, p ≤0.01 (\*\*) or 0.001 (\*\*\*).\
Figure 6---source data 1.Coexpression of EphA7 with markers of proliferation, specification, and differentiaion.](elife-53689-fig6){#fig6}

Because the *EphA7*^-/-^ mouse used is a conventional knockout, it is possible that some of the effects noted during development and regeneration in vivo are due to loss of EphA7 in nonmuscle cell types. Other cell types resident in the muscle have been shown to modify satellite cell-mediated muscle regeneration, particularly fibroadipogenic progenitor cells (FAPs) ([@bib17]; [@bib32]). To address this, we queried existing expression datasets for FAPS specifically as well as for all muscle-associated cells. EphA7 is not expressed by FAPS either during homeostasis or injury (based on bulk RNA-seq, [@bib17]). Combined with the presence of the phenotype during both development and regeneration, the persistence of the phenotype in muscle cell culture ex vivo, and the recapitulation of the phenotype in myogenic cell lines carrying engineered mutations (below), we propose that expression of EphA7 by myocytes is the primary driver of the in vivo and in vitro phenotype we describe here.

Exogenous EphA7 ectodomain induces myogenic differentiation in *EphA7*^-/-^ and WT satellite cells {#s2-5}
--------------------------------------------------------------------------------------------------

While these data suggest that expression of EphA7 promotes myogenic differentiation, they do not distinguish between a cell-autonomous or a non-cell-autonomous mechanism. Eph:ephrin signaling can be either 'forward' (Ephs act as receptors) or 'reverse' (Ephs act as ligands), thus a cell-autonomous mechanism would suggest failure of *EphA7*^-/-^ cells to receive a signal, while a non-cell-autonomous mechanism would suggest loss of the signal itself. Because EphA7 expression is limited to myocytes and loss of EphA7 appears to affect myoblasts, we hypothesized that in this context EphA7 acts non-cell-autonomously via reverse signaling. If this is correct, then expression of EphA7 should be dispensable provided that exogenous EphA7 is present in the culture; furthermore, only the ectodomain (rather than the full-length protein) should be sufficient for this effect. We would therefore predict that exposure to EphA7 ectodomain would rescue the differentiation delay observed in *EphA7*^-/-^ cells and enhance differentiation of WT cells by acting as a proxy for high cell density. To test this, we plated WT and *EphA7*^-/-^ cells at equivalent densities on either laminin-coated coverslips or laminin-coated coverslips functionalized with a chimeric EphA7 ectodomain fused to human Fc (EphA7-Fc) (R&D Systems). Every 12 hours, we assayed the fraction of cells that had differentiated (as measured by expression of myogenin). We found that even at the earliest time assayed (12 hours after plating), the fraction of *EphA7*^-/-^ cells on EphA7-Fc scoring positive for myogenin was equivalent to that of WT cells on laminin, while WT cells on EphA7-Fc differentiated to a greater extent than WT cells on laminin alone ([Figure 7A](#fig7){ref-type="fig"}). These results were consistent over the course of the assay, and by 48 hours of exposure *EphA7*^-/-^ cells stimulated with EphA7-Fc showed myogenin expression and differentiated morphologies indistinguishable from WT ([Figure 7B](#fig7){ref-type="fig"}). We therefore conclude that EphA7 acts non-cell-autonomously as a myocyte-derived signal to promote rapid, synergistic terminal differentiation in local myoblasts, consistent with observations of the community effect.

![Exogenous EphA7 extracellular domain rescues differentiation of *EphA7*-/- satellite cells.\
WT and *EphA7*^-/-^ cells were cultured on coverslips coated with either laminin alone (lam) or laminin functionalized with EphA7-Fc chimera (A7--Fc) in growth medium (F-12 + 15% horse serum). (**A**) 12 hours of exposure to EphA7-Fc rescued differentiation of *EphA7*^-/-^ cells (scored by expression of myogenin) to WT levels, while more WT cells on EphA7-Fc were differentiated than on laminin. Error bars = SEM, p ≤ 0.01 (\*\*), 0.001 (\*\*\*) or 0.0001 (\*\*\*\*). (**B**) *EphA7*^-/-^ myoblasts acquire morphological and molecular characteristics of differentiated myocytes similar to WT cells when exposed to EphA7-Fc. Scale bars = 50 μm.](elife-53689-fig7){#fig7}

Ephrin-A5 expressed on myoblasts mediates the effects of EphA7 {#s2-6}
--------------------------------------------------------------

If EphA7 is signaling in reverse to myoblasts in order to promote their differentiation, we would expect there to be an ephrin (most likely an ephrin-A) present on myoblasts which can transduce the EphA7 signal to promote myogenic differentiation. In multiple contexts in vivo, EphA7 signals in reverse through ephrin-A5 ([@bib14]; [@bib30]), and in an expression screen for all mammalian ephrins on WT and *EphA7*^-/-^ satellite cells we noted that ephrin-A5 is present on cells of both strains but shows increased expression in *EphA7*^-/-^ cells ([Figure 8A](#fig8){ref-type="fig"}). This is consistent with upregulation of ephrin-A5 in other contexts in the *EphA7*^-/-^ mouse ([@bib30]). If ephrin-A5 is the EphA7 receptor, we would expect that cells lacking ephrin-A5 would phenocopy the *EphA7*^-/-^ cells\' differentiation defect, but that unlike *EphA7*^-/-^ cells they should not be rescued by exogenous EphA7 ectodomain. To test this, we generated ephrin-A5^KO^ C2C12 cells using a double-nickase strategy and isolated a clonal population carrying an inactivating deletion, as well as a similar clonal population of EphA7^KO^ C2C12 cells ([Figure 8B](#fig8){ref-type="fig"}); we refer to these mutant cell lines as \'KO\' to avoid confusion with mutant cells from the null mouse (*EphA7*^-/-^). Importantly, EphA7^KO^ C2C12 cells phenocopy primary myoblasts from *EphA7*^-/-^ mice with lower levels of myogenin expression, fewer, smaller myotubes with fewer nuclei, and sustained proliferation even at high density. We compared unedited, EphA7^KO^, and ephrin-A5^KO^ C2C12 cells grown in high serum at either high or low density, in the presence or absence of EphA7-Fc ([Figure 8C](#fig8){ref-type="fig"}). While all three lines showed minimal expression of myogenin (indicating a lack of differentiation) at low density on an unmodified laminin substrate, unedited C2C12 cells increased their differentiation when grown at high density as would be predicted by the community effect, while EphA7^KO^ and ephrin-A5^KO^ cells did not. In contrast, modifying the substrate with EphA7-Fc led to increased differentiation in both unedited and EphA7^KO^ cells, even at low density and high serum, while differentiation in ephrin-A5^KO^ cells was not rescued. When high density was combined with exposure to EphA7-Fc, differentiation by EphA7^KO^ and ephrin-A5^KO^ cells was not significantly different from their response to EphA7-Fc at low densities, while unedited C2C12 cells showed even more enhanced differentiation.

![Ephrin-A5 meets the criteria for the EphA7 receptor on myoblasts.\
(**A**) Ephrin-A5 is expressed at higher levels on *EphA7*^-/-^ adult primary myogenic cells than it is on WT. (**B**) Mutations were made in the EphA7 and ephrin-A5 coding sequences of C2C12 myoblasts using double-nickase targeting, and single clones were expanded and analyzed by RT-PCR for inactivating mutations. Note: The red box in B indicates provisional sequencing of the targeted mutation in EphA7. (**C**) In high serum conditions, differentiation (indicated by expression of myogenin) is minimal in low density cultures of unedited, EphA7^KO^, and ephrin-A5^KO^ C2C12 cells. Unedited C2C12 cells respond to high density by differentiating even in the presence of high serum, but EphA7^KO^ and ephrin-A5^KO^ C2C12 cells do not. At either low or high densities, unedited and EphA7^KO^ C2C12 cells differentiate in high serum in response to exposure to EphA7-Fc, but ephrin-A5^KO^ C2C12 cells do not. Table shows all significance comparisons by density, substrate, and genotype. (**D**) Unedited and EphA7^KO^ C2C12 cells phosphorylate ERK1/2 following 10\' exposure to soluble EphA7-Fc to a greater degree than do ephrin-A5^KO^ C2C12 cells; all values were normalized to loading control. Error bars = SEM, p ≤ 0.01 (\*\*), 0.001 (\*\*\*) or 0.0001 (\*\*\*\*). Scale bars = 50 μm.\
Figure 8---source data 1.Expression of myogenin in unedited, EphA7KO, and ephrin-A5KO cells at high and low density, with and without exogenous EphA7-Fc.](elife-53689-fig8){#fig8}

Reverse signaling by EphAs is less common than by EphBs, as ephrin-As are GPI-linked and thus lack an intracellular domain which would directly transduce the signal. However, in the case of EphA7:ephrin-A5 interactions, other groups have identified reverse signaling interactions that affect cell migration, adhesion, and lineage commitment ([@bib22]; [@bib12]; [@bib44]). One mechanism by which ephrin-A5 can transduce the EphA7 signal is via recruitment of Fyn, a nonreceptor tyrosine kinase that activates downstream effectors such as Src, ERK, Rac, AKT, paxillin and p75; in other cellular contexts this interaction regulates integrin-mediated signaling and adhesion, cell growth and survival, cytoskeletal remodeling, and cell motility ([@bib13]; [@bib27]). To test whether intracellular signaling following EphA7 stimulation is affected in ephrin-A5^KO^ cells, we assayed activation of a potential downstream pathway by quantifying ERK1/2 phosphorylation in unedited, EphA7^KO^, and ephrin-A5^KO^ C2C12 cells in response to EphA7-Fc. We found that unedited and EphA7^KO^ C2C12 cells rapidly and robustly phosphorylated ERK1/2, but ephrin-A5^KO^ C2C12 cells have significantly decreased phosphorylation after 10\' of exposure to EphA7-Fc ([Figure 8D](#fig8){ref-type="fig"}). Based on these data, we conclude that ephrin-A5 is a strong candidate for the EphA7 receptor on myoblasts.

Taken together, these results support a role for EphA7:ephrin-A5 interactions in induction of terminal differentiation during skeletal muscle development and regeneration, and provide a novel molecular mechanism for the community effect. While several other interactions mediating this effect have previously been described, we believe this study is the first to identify a heterotypic, non-cell-autonomous signal between myogenic cells at distinct stages of differentiation. As such, it provides a mechanism for rapidly amplifying the number of differentiated cells in a population once a sufficient local density has been reached and potential fusion partners are readily available. Further, the observation that cells lacking ephrin-A5 show an even more pronounced failure to differentiate than those lacking EphA7 suggests the possibility that threshold levels of ephrin-A5 stimulation may be necessary to initiate even stochastic differentiation.

Discussion {#s3}
==========

Skeletal muscle is unique among vertebrate somatic tissues in that skeletal myofibers, the functional unit of the tissue, are syncytial cells formed by fusion of hundreds or thousands of terminally-differentiated mononuclear cells (myocytes). As such, skeletal muscle is particularly amenable to the use of contact-mediated signaling pathways to induce and coordinate cellular activities such as commitment to differentiation (reviewed in [@bib24]). Indeed, cell-cell contact and adhesion-based signals have been shown to be strongly promyogenic even in the presence of soluble factors that promote myoblast proliferation and thereby inhibit myocyte differentiation. Adhesion proteins such as cadherins, their multifunctional coreceptors Cdo and Boc, and the netrin-3 receptor neogenin are necessary and sufficient to promote robust myogenesis in vitro and in vivo (reviewed in [@bib23]). It is important to note that the enhanced myogenesis brought about by these juxtacrine interactions is distinct from promotion of myocyte fusion, which has recently been shown to require a class of proteins in vertebrate muscle that do not appear to be related to classical contact-mediated signaling ([@bib29]; [@bib35]; [@bib38]; [@bib45]), and instead appears to derive from upregulation of MyoD-dependent transcription (reviewed in [@bib24]).

In this work we present data suggesting that contact-mediated signaling interactions between EphA7 and ephrin-A5 promote collective myogenic differentiation during mammalian muscle development and regeneration. EphA7 is one of a large family of receptor tyrosine kinases that are best characterized as promoting repulsion during cell migration and cell sorting at domain boundaries (reviewed in [@bib41]). However, interactions between Ephs and their ephrin ligands have also been shown to directly affect differentiation: for example, EphB2:ephrinB1 interactions within the osteoblast lineage promote osteoblast differentiation by stimulating nuclear translocation of the transcriptional coactivator TAZ, and in multiple neuronal and stem cell lineages Eph/ephrin signaling modulates cell fate choice both directly and indirectly (reviewed in [@bib43]). EphA7 is a particularly likely candidate for a pro-differentiation molecule because it has been characterized as a tumor suppressor in several cancers ([@bib42]; [@bib33]; [@bib34]) as well as a negative regulator of proliferation through reverse signaling with ephrin-A2 in the adult stem cell niches of the hippocampus ([@bib15]) and hair follicle ([@bib8]). Three different splice variants of EPHA7 have been identified, encoding one full length (FL) and two truncated (T1 and T2) proteins lacking the catalytic kinase domain ([@bib14]), as have two splice variants of ephrin-A5 (one lacking an alternate exon) ([@bib25]). All three EphA7 proteins can signal in reverse via ephrin-A5, and in some contexts such as the closing neural tube the switch from full-length to truncated (T1) EphA7 appears to mediate a switch from repulsive to adhesive interactions ([@bib14]); differential roles for full-length vs. truncated ephrin-A5 are less well described ([@bib26]). In the context of skeletal muscle regeneration, we detected mRNA expression of all three variants of EphA7 and both variants of ephrin-A5 ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}); future work will explore the potential heterogeneity within the population and its mechanistic implications during myogenesis.

Based on our data, we propose a model in which EphA7 non-cell-autonomously promotes rapid and coordinated differentiation in populations of myogenic cells in a density-dependent manner ([Figure 9A](#fig9){ref-type="fig"}). An initially small number of ephrin-A5^+^, EphA7^-^ myoblasts will experience a combination of intrinsic and extrinsic factors that induce them to commit to differentiation, exit the cell cycle, and upregulate myogenin (stochastic commitment). Once this has occurred, these newly-differentiated myocytes will upregulate expression of EphA7, which will signal to adjacent ephrin-A5^+^ myoblasts via cell-cell contact and promote their differentiation (synergistic commitment). This rapidly differentiating population of adjacent cells can subsequently fuse into myotubes/myofibers to form the functional units of skeletal muscle. In the absence of EphA7, while stochastic commitment still occurs, synergistic commitment via the community effect is lost, leading to decreased numbers of myocytes available for fusion ([Figure 9B](#fig9){ref-type="fig"}). Thus, both developmental and regenerative myogenesis still occurs in muscle lacking EphA7, but it progresses more slowly and produces smaller myofibers containing fewer myonuclei. Future studies will identify the mechanism by which EphA7 stimulation is transduced in ephrin-A5 expressing myoblasts, and what the molecular consequences of this interaction are. Given that other molecules which promote specification to myogenesis by cell-cell contact act via upregulation of MyoD-dependent gene transcription, it is intriguing to speculate that upregulation of myogenin and commitment to terminal differentiation could be a direct consequence of EphA7 reverse signaling in myoblasts.

![Proposed model.\
(**A**) We propose a model in which initial, stochastic commitment of individual myoblasts results in their expression of EphA7, which then induces rapid, synergistic commitment of adjacent ephrin-A5-expressing myoblasts via the community effect. (**B**) In the absence of EphA7, stochastic commitment still occurs but synergistic commitment does not, resulting in a decreased number of myocytes and later in fewer, smaller syncytial myofibers.](elife-53689-fig9){#fig9}

Materials and methods {#s4}
=====================

Muscle satellite cell isolation and culture {#s4-1}
-------------------------------------------

All experiments involving mice were conducted in accordance with National Institutes of Health and University of Missouri Institutional Animal Care and Use Committee guidelines. Adult mouse myoblasts were isolated by our published methods ([@bib3]). Briefly, mice were euthanized, hindlimbs removed and skinned, and muscles removed in Dulbecco's PBS (DPBS). Following physical and enzymatic dissociation, cell slurries were filtered and pelleted then plated in Ham\'s F12 (Invitrogen) supplemented with 15% horse serum (Equitech), 5 nM FGF2, and either penicillin/streptomycin (Sigma) or puromycin (Sigma) on gelatin-coated plates. Cells were maintained at 37°C and 5% CO~2~ in a humidified incubator. For differentiation, cells were washed briefly with cold DPBS and switched to Kaighn's F-12 supplemented with 2% horse serum and penicillin/streptomycin or puromycin.

Viable myofiber explants were isolated from EDL muscles using our published methods ([@bib6]; [@bib5]). As above, muscles were dissected, but were not physically dissociated. After collagenase digestion, free-floating myofibers were picked with a glass pipette and transferred into growth medium for culture as above.

EphA7-Fc functionalized coverslips {#s4-2}
----------------------------------

EphA7-Fc functionalized coverslips, together with control laminin-coated coverslips, were freshly prepared the day of seeding. HCl-washed and aminopropyltriethoxysilane (APTES, Acros Organics) treated coverslips were incubated for 3 hours at 37°C with 1--2 mg/mL laminin (Sigma) diluted 1:100 in DPBS. Laminin was then gently aspirated and coverslips were washed twice with DPBS. Half of the coverslips were then incubated for 1.5 hours at 37°C with a 5 µg/mL solution of EphA7-Fc in DPBS, whereas control ones were incubated with only DPBS. The coverslips were washed once with DPBS and placed in multi-well plates with medium for 30\' prior to cell seeding.

In vivo muscle injury {#s4-3}
---------------------

Mice were anesthetized with 1.2% Avertin IP, then 70 μL of sterile 1.2% BaCl~2~ in water was injected into the left TA. Mice were allowed to recover on a warmed platform until the effects of anesthesia were no longer noticeable and experimental injury was confirmed by the presence of foot drop. Mice were housed separately for 3--28 days before the injured muscles were harvested for analysis.

Antibody staining {#s4-4}
-----------------

For fluorescence immunohistochemistry of muscle sections, muscles were flash-frozen in liquid nitrogen-cooled isopentane and sectioned on a Leica cryostat. For fluorescence immunohistochemistry of mouse embryos, embryos were fixed overnight in 4% paraformaldehyde, washed in PBS, and equilibrated into 15% then 30% sucrose in PBS prior to freezing and sectioning.

For fluorescence immunocytochemistry of cultured cells, satellite cells prepared as described above were replated onto gelatin- or laminin-coated glass coverslips, allowed to adhere for 2 hr, then cultured for 12--96 hours and fixed in 4% ice-cold paraformaldehyde. Coverslips were blocked for 1 hour at room temperature with 10% normal goat serum containing 0.2% Triton X-100 then incubated with primary antibody diluted in 10% NGS overnight at 4°C. Coverslips were washed 3 × 10\' in PBS then incubated with secondary antibodies diluted in 10% NGS for 1 hour at RT, washed again, and mounted with Vectashield (Vector) with DAPI. For staining of adult myofiber-associated satellite cells, myofibers at the timepoints indicated in the text were fixed in 4% PFA, washed in PBS, and arranged on slides for staining as above.

Concentrations of primary antibodies used were rabbit anti-EphA7 (Santa Cruz Biotechnology, Inc; Antibody Registry AB_2099673) at 1:200; rabbit anti-laminin (Sigma-Aldrich, Antibody Registry AB_477163) at 1:300; mouse anti-eMyHC (clone F1.652, Developmental Studies Hybridoma Bank, Antibody Registry AB_528358) at 1:50; rat anti-CD34 (clone RAM34, eBioscience, Antibody Registry AB_467211) at 1:200; chicken anti-syndecan-4 ([@bib5]) at 1:1500; mouse anti-MyoD (NCL-MyoD1, Leica, Antibody Registry AB_563997) at 1:10; mouse anti-Pax7 (Developmental Studies Hybridoma Bank, Antibody Registry AB_528428) at 1:10; mouse anti-myogenin (F5D, Developmental Studies Hybridoma Bank, Antibody Registry AB_2146602) at 1:5; mouse anti-myosin heavy chain (MF20, Developmental Studies Hybridoma Bank, Antibody Registry AB_2147781) neat. Secondary antibodies were raised in goat and conjugated with Alexa fluorophores (Invitrogen), and used at 1:500.

All fluorescent images were acquired and processed on an Olympus BX61 upright microscope using Slidebook software (Intelligent Imaging Innovations) or ImageJ ([@bib37]). Digital background subtraction was used to remove signal less than or equal to levels present in control samples processed without primary antibody, and was applied equally to the entire field.

For all quantitative comparisons of expression by immunohistochemistry, at least three biological replicates per genotype per timepoint per stain were analyzed; for cells grown on coverslips or single myofibers \> 10 fields/coverslip or \>20 myofibers/animal were scored and summed.

Morphometric analysis {#s4-5}
---------------------

Myofiber cross-sectional area was automatically calculated based on laminin immunohistochemistry and (in injured/regenerated samples) the presence of central nuclei using SMASH ([@bib39]). A minimum of three animals/genotype/timepoint were analyzed.

RT-PCR {#s4-6}
------

Intron-spanning primers were written to amplify EphA7 and ephrin-A5 splice isoforms and MYH3 (eMyHC):

1.  EphA7V1: 5\'AACCGGGAACAGTGTACGTC3\' F; 5\'TGGTGCCTGGAAATTTAAAATGA3\' R

2.  EphA7V2: 5\'TGAGAAAGATCAACGGGAAAGGA3\'; 5\'CTGACAGGTGCTCATTTGTTAC3\' R

3.  EphA7V3: 5\'TCTACTTTCATTGCACCAAAACCT3\' F; 5\'GCCCATCGTGTTTCCTGAGA3\' R

4.  EphrinA5V1: 5\'AGCAACCCCAGATTCCAGAGG3\' F; 5\'ATCGAAAACACGATCATGAACACC3\' R

5.  EphrinA5V2: 5\'TTGTGAGACCAACAAATGACAC3\' F; 5\'CCGTTTGATTGGGAAGGGGA3\' R

6.  MYH3: 5\'CGTTTTGGACATTGCGGGTT3\' F; 5\'ACCGTCCGCATCTGTTGTAG3\' R

RNA was isolated from TA muscle samples and 1.5 μg was used as template for reverse transcription with SuperScript IV RT (Invitrogen). 1/20 of each reaction was used as template for 30 cycles of PCR amplification (except MYH3, which had 25 cycles) with annealing at 55°.

Double-nickase knockout cells {#s4-7}
-----------------------------

CRISPR Double Nickase Plasmid (m2) targeting mouse EphA7 (sc-420197-NIC-2) and ephrin-A5 (sc-420123-NIC-2) were purchased from Santa Cruz Biotechnologies. C2C12 cells were purchased from ATCC and were tested as mycoplasma-free. Cells were transfected with 2 µg of plasmid using Invitrogen Neon transfection system (1050 V; 30 ms; two pulses). 1.5 µg/mL puromycin was added to transfected cells 24 hours after transfection and every 4 days for 15 days then removed for one week. GFP+, puromycin-resistant clones were individually isolated and expanded then screened for inactivating mutations phenotypically and by RT-PCR and Western blot.

EphA7-Fc stimulation of cells and Western blot {#s4-8}
----------------------------------------------

Primary satellite cells or C2C12 cells were cultured to 80% confluency in 10 cm dishes, then starved overnight (DMEM + 0.1% gentamycin). EphA7-Fc was pre-clustered with anti-human secondary antibody by incubating 100 µg/mL EphA7-Fc (R&D Systems) with 20 µg/mL goat anti-human IgG (Invitrogen) in 0.1% BSA for 30\' at room temperature. Cells were washed twice with DPBS then incubated for 10\' at 37 °C with DMEM + 0.5% FBS supplemented with either anti-human IgG/BSA without EphA7-Fc (control cells) or with pre-clustered EphA7-Fc at a final concentration of 5 µg/mL (stimulated cells). Cells were gently washed with cold DPBS and lysed in Pierce Protease+Phosphatase Inhibitor cocktail (Thermo Scientific) for 30\' on ice, then scraped and soluble proteins were isolated by centrifugation. 20 µg of each lysate was separated by SDS-PAGE then transferred to PVDF membrane. Membranes were incubated in StartingBlock TBS (Thermo Scientific) for 2 hours at room temperature then incubated with mouse anti-phospho-ERK1/2 (Sigma; Antibody Registry AB_260729) at 1:2000 overnight. Membranes were washed 3 × 10\' at room temperature with TBS + 0.05% Tween-20 (TBST) then incubated with anti-mouse HRP secondary antibody at 1:20,000 for 1 hour at room temperature. Membranes were washed 3 × 20\' at room temperature with TBST then detected with SuperSignal West Femto Maximum Sensitivity Substrate (Thermo Scientific) and a UVP Camera System. Images were processed with Fiji image processing software. To compare protein loading, membranes were stripped with ReSTORE Plus (Thermo Scientific) then incubated with anti-calnexin (AbCam; Antibody Registry AB_2069006) at 1:2000 as above, except for detection with anti-rabbit HRP secondary antibody at 1:50,000.

Statistical methods {#s4-9}
-------------------

Where indicated, samples were compared in Graphpad Prism by one-way ANOVA (Kruskal-Willis test) followed by Dunn\'s multiple comparison test or Wilcoxson Mann-Whitney test.
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**Acceptance summary:**

In this manuscript the authors provide compelling evidence that EphA7-EphinA5 partnership regulates density-dependent myogenic differentiation. The work is carefully executed and appropriately interpreted. The results provide a mechanistic understanding for the \'community effect\'. The findings of this work will have implications for biologists across multiple fields.

**Decision letter after peer review:**

Thank you for sending your article entitled \"EphA7 promotes myogenic differentiation via cell-cell contact\" for peer review at *eLife*. Your article has been evaluated by three peer reviewers, including Andrew Brack as the Reviewing Editor and Reviewer \#1, and the evaluation has been overseen by Marianne Bronner as the Senior Editor.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission. The full reviews are included below for further information.

Summary:

In this manuscript Arnold et al. report on the essential contribution that EphA7 expression on nascent myofibers makes to the completion of skeletal myogenesis during muscle regeneration. The data fairly support the author\'s model, in which EphA7 expression on the surface of differentiation-committed myogenic progenitors and adjacent myocytes provides a key signal that promotes formation of mature myofibers during muscle regeneration.

The authors propose that localized foci of accelerated myogenesis occurs within high-density of EphA7 expressing cells, according to a stochastic model of progressive spreading of foci of skeletal myogenesis through the \"so-called\" community effect. EphA7-null mice had lower numbers of myofibers, which were smaller in area. Regeneration was compromised/delayed in these mice. Mutation of EphA7 in mice resulted in many fewer myogenin+ cells in vitro, without affecting the percentage of MyoD+ cells. Plating EphA7-null satellite cells on an EphA7-Fc substrate rescued myogenin expression, showing that EphA7 acts in this system as a ligand, rather than a receptor (in a reverse signaling fashion). Overall, the data shown in this manuscript provide novel insights into a largely under-investigated, yet very interesting topic of investigation.

The work presented appears carefully done and the figures are of high quality. There is a lack of experimentation to explain the mechanism of how EphA7 promotes differentiation. However, identification of EphA7 as a participant in a \"community effect\" is interesting. The following comments should be addressed.

Essential revisions:

Confounding variable when using germline deletion of EhrinA7:

1\) The delayed regeneration process observed in EphA7 null mice suggests incomplete skeletal myogenesis in the absence of EphA7. However, given that the studies are performed in a general KO mouse model, it is unclear whether this is a cell autonomous defect of myogenic cells, or it derives from the lack of EphA7 expression in other cell types that might contribute to regeneration. These are the only in vivo data in the manuscript and therefore a key component of the manuscript.

Below we provide some possible solutions to address this limitation:

-- Figure 5 shows a time course of regeneration and concludes that in the absence of EphA7, eMyHC expression persists in unfused myocytes or mononucleated fibers. A problem here is that mutation used is global, and the mice begin with only \~40% the number of satellite cells that WT mice have. It is not clear how much of the phenotype might be due to starting with fewer satellite cells vs. compromised/delayed differentiation. One way to address this might be to quantify eMyHC^+^ nascent myofibers at earlier time points (5 dpi). The figure suggests that things may have \"caught up\" to a reasonable extent at that time point, only to be deficient again at later steps. More difficult, but perhaps more rigorous would be to use the Pax7CreER driver with the DTA system to kill off satellite cells, but only \~60% of them, so that an EphA7^+^ mouse with a similar deficit in satellite cell numbers could be compared with EphA7-null mice.

-- The central point is that extracellular EphA7 functions as a ligand to promote differentiation via cell to cell contact. Would a transplantation assay help? For example, transplanting EphA7 null SCs into EphA7 null muscle (increase SC number but no benefit of fusion) versus WT into null. Differentiation/fusion would be scored based on donor cell contribution.

-- Although the optimal strategy would consist in the generation and analysis of a mouse model of cell-specific conditional genetic deletion of EphA7, or experiments of cell transplantation (e.g. EphA7 deficient satellite cells into WT muscles subjected to injury), this reviewer understands that these experiments would require a substantial amount of time. The authors could verify by qPCR that EphA7is only (or most largely) expressed in satellite cells (committed to differentiation) and nascent myofibers, but not in other cell types -- e.g. macrophages, endothelial, FAPs -- isolated from regenerating muscles at different time points post-injury. I also note that equivalent information could be retrieved by publicly available RNAseq datasets on muscle-derived cells isolated during muscle regeneration. Overall, providing definitive evidence that EphA7 expression is mostly confined to myoblasts and myofibers within regenerating muscles, as also suggested by immunofluorescence analysis in muscle sections (Figure 1), could in my opinion wave the request of generating mice with cell-specific conditional genetic deletion of EphA7.

Further characterization of Eph and Ehprin expression:

2\) Addition of extracellular domain induces differentiation to WT and KO, suggesting EphA7 must bind to another receptor. What is the Ephin is expressed in myoblasts? Are there other EphA and Ephrin proteins expressed in myocytes and myoblasts.

3\) Eph receptors are probably best known for acting in cell repulsion events in CNS development. In the Discussion, it is mentioned that one of the truncated splice variants of EphA7 promotes cell adhesion, which would better fit its role in myogenic differentiation. It should be straightforward to determine which isoforms are present in differentiating satellite cell cultures, helping to explain what is presumably an adhesion, not repellent, function.

Further characterization of Ephrin A7 molecular function:

4\) Does ectodomain regulate differentiation in clonal or low-density cultures (avoid cell to cell contact). It shouldn\'t if the authors model is correct.

5\) Does the ectodomain act as a decoy receptor? Measure RTK signaling in WT, null and Ectodomain-Fc cultures.

6\) Does EphrinA7 act as a soluble ligand? Add ectodomain to media or in Boyden chamber and examine phenotypes.

Need for further quantification of data:

7\) Figure 1 -- needs quantification and statistical analysis of% of eMyHC positive fibers that also express EphA7 expression, and vice versa, at the different timepoints. Given that expression of EphA7 seems mostly confined to nascent fibers, it would be also informative to perform a quantification of eMyHC and EphA7 by PCR in the whole muscles at each of the timepoints. This analysis will also inform on whether the regulation of EphA7 expression during muscle regeneration occurs at the transcriptional or post-transcriptional level.

8\) Still in Figure 1, the authors should perform immunofluorescence analysis of EphA7 expression in satellite cells, as there is clearly a laminin-associated green staining (EphA7) observed in muscle sections at 5 dpi that could derived from satellite cells. Co-staining with MyoD, Myogenin or Pax7 should be performed to fully address this issue. This data should also corroborate conclusions from Figure 2.

9\) Figure 5D needs statistical analysis. Also, it is stated that, \"we find that muscle myofiber hypertrophy is delayed in *EphA7*^-/-^ muscles, even after taking into account the original deficit in fiber size\". An additional graph and statistics should compare uninjured and 28 dpi EphA7-null fiber sizes to provide evidence for this conclusion.

Reviewer \#1:

In this manuscript, Arnold et al. demonstrate a role for the EphA7 in muscle differentiation.

The authors use a combination of in vivo mouse genetics, expression analysis and cell culture to argue that the EphA7 is expressed in myocytes to promote differentiation of neighboring myoblasts. functions as a ligand. Experiments are performed to a high standard. The authors conclusions are consistent with the data.

I have a few points that are important to address:

Addition of extracellular domain induces differentiation to WT and KO. Therefore it must bind to another receptor.

What is the Ephin is expressed in myoblasts?

Are there other EphA and Ephrin proteins expressed in myocytes and myoblasts?

Does ectodomain regulate differentiation in clonal or low density cultures (avoid cell to cell contact)? It shouldn\'t if the authors model is correct.

Does the ectodomain act as a decoy receptor? Measure RTK signaling in WT, null and Ectodmain-Fc cultures?

Does EphrinA7 act as a soluble ligand? Add ectodomain to media or in Boyden chamber and examine phenotypes.

Reviewer \#2:

In this manuscript Arnold et al. report on the essential contribution that EphA7 expression on nascent myofibers makes to the completion of skeletal myogenesis during muscle regeneration. The data fairly support the author\'s model, in which EphA7 expression on the surface of differentiation-committed myogenic progenitors and adjacent myocytes provides a key signal that promotes formation of mature myofibers during muscle regeneration.

The authors propose that localized foci of accelerated myogenesis occurs within high-density of EphA7 expressing cells, according to a stochastic model of progressive spreading of foci of skeletal myogenesis through the \"so-called\" community effect.

Overall, the data shown in this manuscript provide novel mechanistic insights into a largely under-investigated, yet very interesting topic of investigation.

Some additional piece of experimental evidence in support to the proposed model would further strength this manuscript, as indicated in the specific points -- see below.

1\) Figure 1 -- needs quantification and statistical analysis of% of eMyHC positive fibers that also express EphA7 expression, and vice versa, at the different timepoints. Given that expression of EphA7 seems mostly confined to nascent fibers, it would be also informative to perform a quantification of eMyHC and EphA7 by PCR in the whole muscles at each of the timepoints. This analysis will also inform on whether the regulation of EphA7 expression during muscle regeneration occurs at the transcriptional or post-transcriptional level.

2\) Still in Figure 1, the authors should perform immunofluorescence analysis of EphA7 expression in satellite cells, as there is clearly a laminin-associated green staining (EphA7) observed in muscle sections at 5 dpi that could derived from satellite cells. Co-staining with MyoD, Myogenin or Pax7 should be performed to fully address this issue. This data should also corroborate conclusions from Figure 2.

3\) The delayed regeneration process observed in EphA7 null mice suggests incomplete skeletal myogenesis in the absence of EphA7. However, given that the studies are performed in a general KO mouse model, it is unclear whether this is a cell autonomous defect of myogenic cells, or it derives from the lack of EphA7 expression in other cell types that might contribute to regeneration. Although the optimal strategy would consist in the generation and analysis of a mouse model of cell-specific conditional genetic deletion of EphA7, or experiments of cell transplantation (e.g. EphA7 deficient satellite cells into WT muscles subjected to injury), this reviewer understands that these experiments would require a substantial amount of time. I rather suggest that the authors verify by qPCR that EphA7is only (or most largely) expressed in satellite cells (committed to differentiation) and nascent myofibers, but not in other cell types -- es macrophages, endothelial, FAPs -- isolated from regenerating muscles at different time points post-injury. I also note that equivalent information could be retrieved by publicly available RNAseq datasets on muscle-derived cells isolated during muscle regeneration. Overall, providing definitive evidence that EphA7 expression is mostly confined to myoblasts and myofibers within regenerating muscles, as also suggested by immunofluorescence analysis in muscle sections (Figure 1), would in my opinion wave the request of generating mice with cell-specific conditional genetic deletion of EphA7.

4\) Figure 7B. By close inspection of the pictures it seems to this reviewer that satellite cell cultures from EphA7 null mice display evident morphological differences, as compared to WT cultures, regardless of the presence of EphA7-Fc. In particular, there are several phalloidin-positive flat cells showing a phenotype reminiscent of senescent or endothelial like cells. The authors should better analyze and explain these morphological discrepancies, and understand whether they are due to FACS contamination, cultural artifacts or a reproducible acquisition of lineage heterogeneity by satellite cells, caused by EphA7 deficiency.

5\) Figure 8. The proposed model is not of \"immediate catch\" by first glance. Furthermore, the understanding of this figure is limited by lack of color identity information for nuclear purple and nuclear green. I suggest that the authors substantially revise this figure to make their proposed model clearer.

Reviewer \#3:

This manuscript reports on the role of EphA7 in differentiation of skeletal muscle precursor cells. This is related to the \"community effect\" first described by Gurdon, an interesting phenomenon for which few molecular regulators have been identified. The authors carefully document the expression pattern of EphA7 in developing and regenerating skeletal muscle, and also in satellite cells on isolated myofibers and in primary culture in vitro. EphA7 is induced in differentiating cells, correlating temporally with myogenin and MyHC expression. EphA7-null mice had lower numbers of myofibers, which were smaller in area. Regeneration was compromised/delayed in these mice. Mutation of EphA7 in mice resulted in many fewer myogenin+ cells in vitro, without affecting the percentage of MyoD+ cells. Plating EphA7-null satellite cells on an EphA7-Fc substrate rescued myogenin expression, showing that EphA7 acts in this system as a ligand, rather than a receptor (in a reverse signaling fashion).

The work presented appears carefully done and the figures are of high quality. There is a lack of experimentation to explain mechanisms of how EphA7 promotes differentiation or how its expression is induced, which may detract from publication in a journal like *eLife*. However, identification of EphA7 as a participant in a \"community effect\" is interesting. The following comments should be addressed.

1\) Figure 5 shows a time course of regeneration and concludes that in the absence of EphA7, eMyHC expression persists in unfused myocytes or mononucleated fibers. A problem here is that mutation used is global, and the mice begin with only \~40% the number of satellite cells that WT mice have. It is not clear how much of the phenotype might be due to starting with fewer satellite cells vs. compromised/delayed differentiation. One way to address this might be to quantify eMyHC^+^ nascent myofibers at earlier time points (5 dpi). The figure suggests that things may have \"caught up\" to a reasonable extent at that time point, only to be deficient again at later steps. More difficult, but perhaps more rigorous would be to use the Pax7CreER driver with the DTA system to kill off satellite cells, but only \~60% of them, so that an EphA7^+^ mouse with a similar deficit in satellite cell numbers could be compared with EphA7-null mice.

2\) Figure 5D needs statistical analysis. Also, it is stated that, \"we find that muscle myofiber hypertrophy is delayed in *EphA7*^-/-^ muscles, even after taking into account the original deficit in fiber size\". An additional graph and statistics should compare uninjured and 28 dpi EphA7-null fiber sizes to provide evidence for this conclusion.

3\) Eph receptors are probably best known for acting in cell repulsion events in CNS development. In the Discussion, it is mentioned that one of the truncated splice variants of EphA7 promotes cell adhesion, which would better fit its role in myogenic differentiation. It should be straightforward to determine which isoforms are present in differentiating satellite cell cultures, helping to explain what is presumably an adhesion, not repellent, function.
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Author response

> Essential revisions:
>
> Confounding variable when using germline deletion of EphrinA7:
>
> 1\) The delayed regeneration process observed in EphA7 null mice suggests incomplete skeletal myogenesis in the absence of EphA7. However, given that the studies are performed in a general KO mouse model, it is unclear whether this is a cell autonomous defect of myogenic cells, or it derives from the lack of EphA7 expression in other cell types that might contribute to regeneration. These are the only in vivo data in the manuscript and therefore a key component of the manuscript.
>
> Below we provide some possible solutions to address this limitation:
>
> -- Figure 5 shows a time course of regeneration and concludes that in the absence of EphA7, eMyHC expression persists in unfused myocytes or mononucleated fibers. A problem here is that mutation used is global, and the mice begin with only \~40% the number of satellite cells that WT mice have. It is not clear how much of the phenotype might be due to starting with fewer satellite cells vs. compromised/delayed differentiation. One way to address this might be to quantify eMyHC^+^ nascent myofibers at earlier time points (5 dpi). The figure suggests that things may have \"caught up\" to a reasonable extent at that time point, only to be deficient again at later steps. More difficult, but perhaps more rigorous would be to use the Pax7CreER driver with the DTA system to kill off satellite cells, but only \~60% of them, so that an EphA7^+^ mouse with a similar deficit in satellite cell numbers could be compared with EphA7-null mice.
>
> -- The central point is that extracellular EphA7 functions as a ligand to promote differentiation via cell to cell contact. Would a transplantation assay help? For example, transplanting EphA7 null SCs into EphA7 null muscle (increase SC number but no benefit of fusion) versus WT into null. Differentiation/fusion would be scored based on donor cell contribution.
>
> -- Although the optimal strategy would consist in the generation and analysis of a mouse model of cell-specific conditional genetic deletion of EphA7, or experiments of cell transplantation (e.g. EphA7 deficient satellite cells into WT muscles subjected to injury), this reviewer understands that these experiments would require a substantial amount of time. The authors could verify by qPCR that EphA7is only (or most largely) expressed in satellite cells (committed to differentiation) and nascent myofibers, but not in other cell types -- e.g. macrophages, endothelial, FAPs -- isolated from regenerating muscles at different time points post-injury. I also note that equivalent information could be retrieved by publicly available RNAseq datasets on muscle-derived cells isolated during muscle regeneration. Overall, providing definitive evidence that EphA7 expression is mostly confined to myoblasts and myofibers within regenerating muscles, as also suggested by immunofluorescence analysis in muscle sections (Figure 1), could in my opinion wave the request of generating mice with cell-specific conditional genetic deletion of EphA7.
>
> Further characterization of Eph and Ephrin expression:
>
> 2\) Addition of extracellular domain induces differentiation to WT and KO, suggesting EphA7 must bind to another receptor. What is the Ephin is expressed in myoblasts? Are there other EphA and Ephrin proteins expressed in myocytes and myoblasts.
>
> 3\) Eph receptors are probably best known for acting in cell repulsion events in CNS development. In the Discussion, it is mentioned that one of the truncated splice variants of EphA7 promotes cell adhesion, which would better fit its role in myogenic differentiation. It should be straightforward to determine which isoforms are present in differentiating satellite cell cultures, helping to explain what is presumably an adhesion, not repellent, function.
>
> Further characterization of Eph A7 molecular function:
>
> 4\) Does ectodomain regulate differentiation in clonal or low-density cultures (avoid cell to cell contact). It shouldn\'t if the authors model is correct.
>
> 5\) Does the ectodomain act as a decoy receptor? Measure RTK signaling in WT, null and Ectodomain-Fc cultures.
>
> 6\) Does EphA7 act as a soluble ligand? Add ectodomain to media or in Boyden chamber and examine phenotypes.
>
> Need for further quantification of data:
>
> 7\) Figure 1 -- needs quantification and statistical analysis of% of eMyHC positive fibers that also express EphA7 expression, and vice versa, at the different timepoints. Given that expression of EphA7 seems mostly confined to nascent fibers, it would be also informative to perform a quantification of eMyHC and EphA7 by PCR in the whole muscles at each of the timepoints. This analysis will also inform on whether the regulation of EphA7 expression during muscle regeneration occurs at the transcriptional or post-transcriptional level.
>
> 8\) Still in Figure 1, the authors should perform immunofluorescence analysis of EphA7 expression in satellite cells, as there is clearly a laminin-associated green staining (EphA7) observed in muscle sections at 5 dpi that could derived from satellite cells. Co-staining with MyoD, Myogenin or Pax7 should be performed to fully address this issue. This data should also corroborate conclusions from Figure 2.
>
> 9\) Figure 5D needs statistical analysis. Also, it is stated that, \"we find that muscle myofiber hypertrophy is delayed in *EphA7*^-/-^ muscles, even after taking into account the original deficit in fiber size\". An additional graph and statistics should compare uninjured and 28 dpi EphA7-null fiber sizes to provide evidence for this conclusion.

We have edited the manuscript and figures as well as generated new data and figures, and we thank the reviewers for the significant improvements that their suggestions have made in our manuscript. The most significant change is a new figure (Figure 8) in which we show that ephrin-A5 meets the criteria for the EphA7 receptor in this system, thus providing a more complete mechanism than we had in the previous version; all major revisions are described below.

We have added a new panel to Figure 1 (Figure 1B) in which the co-expression of EphA7 and eMyHC across the timecourse is quantified. As noted in the figure legend, at later timepoints a small fraction of laminin-bounded fibers is scored positive for EphA7 but negative for eMyHC due to the thresholds determined during imaging (normalized to a no-primary control in each case). However, we believe that in actuality there are no EphA7^+^/eMyHC- fibers. We present the data as we do (and with this caveat) because it seems the best and most honest way to approach it, however if the reviewers have suggestions regarding either the data presentation or the text/figure legend we would be grateful for advice. As suggested, we provide an RT-PCR timecourse for all three splice isoforms of EphA7 (and both splice isoforms of ephrin-A5, see below) as well as eMyHC in a supplementary figure (Figure 1---figure supplement 1). We do not draw any mechanistic conclusions from these data in this manuscript because that would require not only protein/RNA resolution at the level of individual cells in situ but downstream signaling analyses; however, we thank the reviewers for suggesting the experiment and plan to follow up on these intriguing results if possible.

We have included a new panel in Figure 5 (G) showing average fiber size in WT and *EphA7*^-/-^ regenerating muscle at each timepoint (in addition to the binned areas shown previously), with statistics comparing genotypes at each timepoint.

We remade Figure 7B, to remove potential confusion regarding cell morphology and identity. We have also included additional text to clarify that except for a higher representation of proliferating cells, there is no obvious difference in the appearance of satellite cell cultures from WT and *EphA7*^-/-^ mice.

To provide a molecular mechanism for the activity of EphA7, we have included new data (now Figure 8) and accompanying text supporting ephrin-A5 as the EphA7 receptor on myoblasts. This figure includes data showing that ephrin-A5 protein expression is increased in *EphA7*^-/-^ primary satellite cells; that in C2C12 cells high density promotes differentiation in unedited but not EphA7^KO^ or ephrin-A5^KO^ cells, while EphA7 ectodomain promotes differentiation in unedited and EphA7^KO^ at either high or low densities but never in ephrin-A5^KO^ cells; and that exposure to EphA7 ectodomain rapidly induces ERK1/2 phosphorylation in unedited and EphA7^KO^ cells which is more than twofold reduced in ephrin-A5^KO^ cells. We are very pleased with this figure and hope that it will be useful to clarify the roles of density, EphA7 as a pro-differentiation stimulus, and ephrin-A5 as the receptor for that non-cell-autonomous stimulus. Due to the Covid-19 lockdown on the MU campus, we were unable to complete the confirmation of the sequence deleted in the EphA7^KO^ line of C2C12s; this uncertainty is indicated graphically on the figure itself.

We remade the model (now Figure 9) to clarify and to include new data. While co-expression of Pax7 and MyoD, and of MyoD and myogenin, are important transient states in myogenesis, knowing this is not necessary to understand the model. We have therefore removed the purple (red + blue) and green (yellow + blue) nuclei to make the model simpler. In addition, since our data now include ephrin-A5 as the EphA7 receptor on myoblasts, we have included this expression in the schematic although it does not change over the course of differentiation.

To address the concern that EphA7 may be expressed in nonmuscle cell types and that this might be responsible for at least some of the observed phenotype, we have consulted with Dr. Fabio Rossi who has generated bulk RNA-seq datasets for the most likely nonmuscle cell type to influence muscle differentiation (FAPs), as well as with Dr. Tom Cheung, Dr. Bradley Olwin, and Dr. Benjamin Cosgrove, who have each independently generated single cell RNA-seq datasets covering all resident cell types. Dr. Rossi confirms that EphA7 is not expressed by FAPs and we note this in the text. However, neither EphhA7 nor ephrin-A5 RNA are detectable in any cell types during muscle regeneration in any of the single-cell datasets we consulted, making interpretation of those data difficult. While we are disappointed that the best we can offer is negative data, based our primary myogenic cell cultures and C2C12 knockout experiments we remain confident that the effect we observe in vivo is primarily or entirely due to myocyte-myoblast interactions. Unfortunately, definitive proof for this will not be available for some time (we are acquiring the ephrin-A5 conditional knockout line from a collaborator as frozen sperm).

We have expanded the text to more explicitly describe the non-cell-autonomous effect we propose, and to note that exposure to the EphA7-Fc would therefore be expected to act as a proxy for high cell density. The data in new Figure 8 are also presented in a way designed to emphasize this point.
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